Company news

Modus Therapeutics Holding AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Modus Therapeutics publishes interim report for Q1 2026

May 26, 2026

Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million

April 27, 2026

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025

April 15, 2026

Modus Therapeutics publishes year-end report for 2025

February 25, 2026

Modus Therapeutics publishes Interim report for the third quarter 2025

November 26, 2025

Interim Report - January-September 2025

November 14, 2025

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

November 4, 2025

Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia

November 3, 2025

Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer

September 18, 2025

Modus resolves on compensation issue to guarantors in completed rights issue

September 2, 2025

Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue

August 28, 2025

Modus Therapeutics raises approximately SEK 28.3 million in oversubscribed unit issue

August 27, 2025

Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue of Units

August 11, 2025

Modus Therapeutics publishes Interim report for the second quarter 2025

August 7, 2025

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin

July 14, 2025

Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million

June 27, 2025

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.